This is similar to the previous study by Goldfarb et al (28) who reported no difference in the decline of AMH levels among pre-menopausal women receiving cyclophosphamide methotrexate and the 5 fluorouracil (CMF) combination; adriamycin, cyclophosphamide and taxane (AC-T) combination, and then taxane and herceptin (TH) for breast cancer. Here, AMH is linked to breast carcinoma.